Novartis AG
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2016 | $11.48B | $9.61B | $1.86B | $846.0M |
| FY2017 | $12.62B | $11.30B | $1.33B | $924.0M |
| FY2018 | $14.27B | $13.02B | $1.25B | $1.01B |
| FY2019 | $13.63B | $12.25B | $1.38B | — |
| FY2020 | $13.65B | $12.38B | $1.28B | $958.0M |
| FY2021 | $15.07B | $14.01B | $1.07B | $910.0M |
| FY2022 | $14.24B | $13.32B | $916.0M | $982.0M |
| FY2023 | $14.46B | $13.40B | $1.06B | $1.14B |
| FY2024 | $17.62B | $16.25B | $1.37B | $1.31B |
| FY2025 | $19.14B | $17.60B | $1.55B | $1.33B |